$EPZM - On our trading list. This analyst made theses comments in the morning. After the close an approval was given by the FDA!Citi boosts Epizyme target to $35, views as potential takeover targetEPZM Despite the recent move higher in the stock, Citi analyst Mohit Bansal continues to see upside in shares of Epizyme. He raised his price target to $35 from $25 and reiterates a Buy rating on the name. The analyst anticipates a "series of upcoming good news" for the company, including potential approval in a smaller epithelioid sarcoma indication this week, acceptance and potential priority review for follicular lymphoma filing by February 18, and potential approval with a broad label by year end 2020. Bansal also sees Epizyme as a takeover candidate with a value of the company at $54 to $64 per share. $EPZM, Epizyme, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page